Surveillance for pancreatic cancer in high-risk individuals

Running title: Outcomes of pancreatic cancer surveillance

I.C.A.W. Konings1*, M.I. Canto2*, J.A. Almario2, F. Harinck1, P. Saxena2,3, A.L. Lucas4, F. Kastrinos5, D.C. Whitcomb6, R.E. Brand5, J. Lachter7, G. Malleo8, S. Paiella8, S. Syngal9, J.R. Saltzman9, E.M. Stoffel10, J.E. van Hooft11, R.H. Hruban12, J.W. Poley1, P. Fockens11, M.G. Goggins2, and M.J. Bruno1

On behalf of the International Cancer of the Pancreas Screening (CAPS) Consortium

1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
2 Department of Gastroenterology and Hepatology, the Johns Hopkins Medical Institutions, Baltimore, United States of America
3 Department of Gastroenterology and Hepatology, Royal Prince Alfred Hospital, Camperdown NSW, Australia
4 Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States of America
5 Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, United States of America
6 Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, United States of America
7 Department of Gastroenterology, Rambam Healthcare Campus, Haifa, Israel
8 Department of General Surgery, University Hospital of Verona, Italy
9 Department of Gastroenterology, Brigham and Women’s Hospital and Population Sciences Division, Dana Farber Cancer Institute, Boston, United States of America
10 Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
11 Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
12 Department of Pathology, The Sol Goldman Pancreatic Cancer Research center, the Johns Hopkins Medical Institutions, Baltimore, United States of America

* Authors contributed equally to the manuscript

Corresponding author:

Ingrid C.A.W. Konings
Erasmus MC, University Medical Center Rotterdam
P.O. Box 2040
3000 CA Rotterdam, The Netherlands
i.konings@erasusmc.nl
+31 10 70 32983

Grant support: No funding was obtained for this study

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/bjs5.50180
Manuscript type: Original article

The paper is not based on a previous communication to a society or meeting

Abbreviations:

APC, adenomatous polyposis coli; ATM, ataxia telangiectasia mutated; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; FAMMM, familial atypical multiple mole melanoma syndrome; FDR, first degree relative; HBOC, hereditary breast and ovarian cancer; HRI, high-risk individuals; HRN, high-risk neoplastic precursor lesion; IPMN, intraductal papillary mucinous neoplasm; MMR, mismatch repair genes; MRI, magnetic resonance imaging; PanIN, pancreatic intraepithelial neoplasia; PanNET, pancreatic neuroendocrine tumour; PDAC, pancreatic ductal adenocarcinoma; SDR, second degree relative.

Conflict of interest: None of the authors have anything to disclose

Author contributions to manuscript:

I.C.A.W. Konings: study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, statistical analysis; M.I. Canto: study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision, study supervision; J.A. Almario: acquisition of data, critical revision; F. Harinck: acquisition of data, critical revision; P. Saxena: study concept and design, critical revision; A.L. Lucas: acquisition of data, critical revision; F. Kastrinos: acquisition of data, critical revision; D.C. Whitcomb: acquisition of data, critical revision; R.E. Brand: acquisition of data, critical revision; J. Lachter: acquisition of data, critical revision; G. Malleo: acquisition of data, critical revision; S. Paiella: acquisition of data, critical revision; S. Syngal: acquisition of data, critical revision; J.R. Saltzman: acquisition of data, critical revision; E.M. Stoffel: acquisition of data, critical revision; J.E. van Hooft: acquisition of data, critical revision; R.H. Hruban: acquisition of data, critical revision; J.W. Poley: acquisition of data, critical revision; P. Fockens: acquisition of data, critical revision; M.G. Goggins: acquisition of data, critical revision; and M.J. Bruno: study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision, study supervision

Keywords: pancreatic cancer; surveillance; pancreas; pancreatic tumours; pancreatic surgery; outcome; survival
ABSTRACT

Background

Surveillance of high-risk individuals for pancreatic ductal adenocarcinoma (PDAC) and its precursors might lead to better outcomes. The aim of this study was to determine prevalence and outcomes of PDAC and high-risk neoplastic precursor lesions among such patients participating in surveillance programmes.

Method

A multicentre study was conducted through the International CAPS Consortium Registry to identify high risk individuals who had undergone pancreatic resection or progressed to advanced PDAC while under surveillance. High-risk neoplastic precursor lesions were defined as: pancreatic intraepithelial neoplasia 3 (PanIN-3), intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia and pancreatic neuroendocrine tumours (PanNET) equal to or greater than 2 cm in diameter.

Results

Of 76 high risk individuals identified in 11 surveillance programmes; 71 had undergone surgery and 5 had been diagnosed with inoperable PDAC. Of the 71 resections 32 (45%) had PDAC or a high-risk precursor (19 PDAC, 4 main duct IPMN, 4 branch duct IPMN, 5 PanIN-3; the other 39 patients had lesions thought to be associated with lower risks of neoplastic progression. Age ≥65, female gender, carriage of a gene mutation and location of a lesion in the head/uncinate region were associated with high-risk precursor lesions or PDAC. The survival of high risk individuals with low-risk neoplastic lesions versus those with high-risk precursor lesions did not differ. Survival was worse among patients with PDAC. There was no surgery-related mortality.

Conclusion

A high proportion of high risk individuals who underwent surgical resection for screen or surveillance-detected pancreatic lesions had a high risk neoplastic precursor lesion or PDAC at the time of surgery. Survival was better in high risk individuals who had either low or high-risk neoplastic precursor lesions compared to those who had developed PDAC.

Word count: 248 words
INTRODUCTION

Despite improvements in treatments for PDAC, it remains the third leading cause of cancer deaths in the United States (U.S.) with a 5-year survival of only 8%\(^1\). By 2030, PDAC is projected to become the second leading cause of cancer-related death in that country\(^2\). Advances in screening, prevention, and treatment have the potential to change pancreatic cancer incidence and death rates\(^2\). Inherited susceptibility is thought to be a major factor in the development of PDAC, accounting for 5-10% of cases\(^3\). Surveillance for PDAC and its precursor lesions in asymptomatic high-risk individuals is increasingly being performed worldwide\(^4\)-\(^15\). These high-risk individuals can be categorized into two groups: carriers of known PDAC-associated gene mutations (especially carriers of deleterious mutations in \( \text{CKDN2A}, \text{BRCA2}, \text{BRCA1}, \text{ATM}, \text{TP53}, \text{PRSS1} \) or \( \text{STK11} \)), and first-degree relatives in familial PDAC (clustering of at least two first-degree blood relatives with PDAC)\(^16\). The goals of surveillance have been previously described by the CAncer of the Pancreas Screening (CAPS) Consortium\(^17\). These include the detection and treatment of early invasive pancreatic cancer (T1N0M0) at baseline or follow-up; detection and treatment of any invasive resectable cancer at baseline screening; detection and treatment of multifocal pancreatic intraepithelial neoplasia 3 (PanIN-3); and the detection and treatment of intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia.

Few studies have described the surgical pathology findings in high-risk patients who have undergone surgery\(^15\)-\(^18\). The CAPS Consortium Registry was created to gather information rapidly about the experience of surveillance. In this study, we evaluated the diagnostic yield and outcomes of high-risk individuals who underwent surgical resection or progressed to invasive cancer and examined the characteristics of patients who developed high-risk neoplastic precursor lesions or PDAC.
METHODS

All participating centres in the CAPS Consortium (36 centres, 9 countries) were requested to enter patient information data for high-risk individuals participating in their PDAC-surveillance programmes who had either undergone pancreatic surgery because of the detection of a suspicious pancreatic lesion, or who had progressed to advanced non-resectable malignant disease. Data were collected through the use of web-based software (OmniComm™ Electronic Data Capture). Anonymized clinical and demographic information was collected relating to gender, age, tobacco and alcohol use, diabetes mellitus, history of pancreatitis, body mass index (BMI), known gene mutations, and family history of PDAC. In addition, pancreatic imaging modalities that detected the lesions, characteristics of the lesions detected by imaging, timing of detection, therapy, pathology and outcomes after surgery or diagnosis of advanced PDAC were also recorded. Research protocols of all participating centres were largely based on the consensus statements of the Cancer of the Pancreas Screening (CAPS) Consortium produced in 2013, acknowledging that the nature of this study and its time span made it inevitable that differences between protocols of screening centres would exist. The index examinations and follow-up examinations were carried out using MRI and/or endoscopic ultrasonography. However, when suspect lesions were detected, other modalities, such as CT imaging, were often used for further characterization and staging. All individuals in this study provided written informed consent for their participation in the respective PDAC surveillance programmes as approved by the Ethical Committees of the participating centres and the study was conducted in accordance with the Declaration of Helsinki.
Participants with pathologically proven high-risk neoplastic precursor lesions or pathologically proven PDAC were compared to participants who underwent surgery but in whom the resection specimen harboured no high-risk precursor lesion or PDAC. HRN were defined as uni- or multifocal PanIN-3 lesions, main and branch-duct duct IPMNs with high-grade dysplasia and PanNETs $\geq 2$ cm$^{19,20}$. 

**Statistical methods**

Descriptive statistics were used to characterize patient and lesion characteristics. Univariable analyses (Chi square, or Fisher’s exact test where indicated) were performed on possible risk factors associated with PDAC or high-risk neoplasia precursor lesions. All variables with a $P$-value $<0.200$ in the univariable analyses were included in the multivariable analysis. Survival comparisons for different subgroups were plotted as Kaplan-Meier curves and hazard ratios calculated using Log Rank. All analyses were conducted using the Statistical Package for the Social Sciences (V.21, SPSS Institute, Chicago, Illinois, USA).

**RESULTS**

**Patient characteristics**

A total of 76 high risk individuals were included from 11 PDAC-surveillance programmes in 4 countries (United States, The Netherlands, Israel, Italy). Between the 11 centres, some 1700 patients considered to be at high-risk underwent surveillance, of whom approximately 70% were female, Of the 76 included with precursor lesions, 5 were diagnosed with advanced disease during surveillance and 71
underwent surgery for a suspected lesion of whom two were discovered to have inoperable disease.

Baseline characteristics of all 76 high-risk individuals are summarized in Table 1.

**High-risk neoplastic precursor lesions and (advanced) pancreatic ductal adenocarcinoma**

High-risk neoplastic precursor lesions or PDAC were present in the surgical specimens of 32 (45%) of the 71 patients who underwent surgery. Among these, five (7%) patients had PanIN-3 lesions as the highest grade neoplastic lesion, four (6%) a branch-duct IPMN with high-grade dysplasia, four (6%) a main-duct IPMN, and 19 (27%) had PDAC. Pathology findings in all 71 high risk individuals who underwent surgery are summarized in Table 2, as well as lesion characteristics and type of surgery.

In 39 high-risk individuals, (55%) the indication for surgery was detected at their baseline screening evaluation. Of the remaining 32 (45%) patients, lesions were detected at follow-up investigations. In 9 of these 32 patients, a lesion was already present at previous investigations, for a mean time of 9 months prior to resection. These lesions initially did not meet resection criteria, but a changing appearance with time led to resection. In 10 of these 32 patients, there were mean delays of 7 months from their recommended screening interval (recommended screening intervals ranged from 3-24 months, depending on visualization and type of lesion). EUS detected the vast majority of lesions (87.3%). A total of 93 suspicious lesions were detected in the 71 patients who underwent surgery, of which 44 (47%) were cystic and 33 (36%) solid in appearance. Mean size of these 93 lesions was 14 mm, ranging between 3 to 51 mm.

Distal pancreatectomy was performed in 36 patients (51%) and a pancreaticoduodenectomy in 18 (25%). Complications of surgery were seen in 34 (48%) patients. The most common complications
were infection (14%), delayed gastric emptying (9%) and pancreatic fistula (6%). There were no surveillance or surgery-related deaths.

Of the five patients diagnosed with advanced disease during surveillance, three (60%) were identified at follow-up, the other two were detected at baseline evaluation.

Outcomes

The outcomes of both risk groups are summarized in Table 3. Of all 76 included patients, 61 (80%) are still alive, a mean 52 months after surgery or diagnosis of PDAC. Of 71 (83%) high risk individuals who underwent surgery 59 are still alive after surgery after a mean follow up of 54 months. Of the 12 patients who have died, 8 deaths were PDAC-related. Survival was significantly poorer for individuals with advanced PDAC as compared to the individuals who underwent surgery (survival 40% vs 83%, \( P = 0.05 \); mean 10 vs 54 months, \( P < 0.001 \)). Only 2 (3%) of 71 high risk patients who underwent surgery died within a year (all-cause 1-year mortality), compared to 2 of 5 with advanced PDAC; 52% survived more than 3 years after surgery.

Risk factors

Univariable analyses for factors associated with high-risk neoplastic precursor lesions or PDAC in the resection specimen (see Table 4) included age \( \geq 65 \) at the time of surgery (OR 4.1, \( P = 0.007 \)) and female gender (OR 3.8, \( P = 0.007 \)). In the multivariable analysis, four factors were significantly associated with the presence of a high-risk precursor lesion or PDAC in the pancreatic resection specimen: age \( \geq 65 \) at the time of surgery (OR 7.5, \( P = 0.010 \)), female gender (OR 5.8, \( P = 0.017 \)), carriage of a deleterious
mutation in a known pancreatic cancer susceptibility gene (OR 4.9, \( P = 0.040 \)) and location of a lesion in the head/uncinate region of the pancreas (OR 4.2, \( P = 0.041 \)).

**Survival analysis**

The pancreatic neoplasia grade was significantly associated with overall survival in high-risk individuals. Figure 1 shows the Kaplan-Meier curve for different pathologic subgroups. High-risk individuals with no or low-risk neoplastic lesions (group A, 39) and high-risk individuals with high-risk neoplastic precursor lesions (group B, 13) had the best survival, followed by those with stage I or II PDAC (group C, 16), and those with stage III or IV PDAC (group D, 8). The hazard ratio for group B compared to group A was 4.5 (\( P = 0.163 \)), compared to group C, 13.1 (\( P < 0.001 \)), and compared to group D, 25.3 (\( P < 0.001 \)).

**DISCUSSION**

In this multicentre international study, high-risk neoplastic lesions or PDAC were present in 45% of the high-risk population that underwent surgery in a PDAC-surveillance programme. Survival between high-risk patients with no or low-risk lesions versus those with high-risk neoplastic precursor lesions did not differ significantly. The patients who developed PDAC had a significantly higher overall mortality and poorer survival compared to those with no or low-risk neoplastic lesions.

Surveillance of high-risk individuals has the potential to improve the poor survival of PDAC and is increasingly being undertaken. In 2010, the CAPS Consortium was formed to help organize global
pancreatic surveillance. By pooling data from participating centres, important research questions pertaining to pancreatic surveillance can be assessed readily. The present analysis reports the pooled data of high-risk individuals for whom surveillance led to the detection of advanced disease or a lesion for which pancreatic surgery was performed.

Goals of surveillance previously described by the CAPS Consortium 17 were early invasive cancers (T1N0M0), PanIN-3, main duct IPMNs and branch duct IPMNs with high-grade dysplasia. While PanNETs ≥ 2 cm were also included in the definition no such large PanNETs were detected. Timing of intervention is an important issue. In this series, 55% of the resection specimens harboured no high-risk neoplastic precursor lesion or PDAC, but did contain, for example, low-risk PanIN lesions (PanIN-1 or 2) or small PanNETs. Only long-term follow-up will disclose whether patients with resected low-risk lesions might have a reduced risk of subsequently developing PDAC. For some patients, surgical resection was performed too late, as only 3 of the 19 PDACs were T1. The main challenge in any surveillance programme is how to distinguish between those individuals that can be safely monitored and those who require surgery to resect a neoplastic lesion at a curable stage.

In this study, 55% of lesions that prompted surgery were detected at a baseline visit. This could raise the question whether one-time screening of high-risk individuals at a given age is also effective. Alternatively, when an advanced lesion is found at the index investigation, it could be argued that this lesion might have been detected at an earlier stage with potentially a better outcome if surveillance had started at an earlier age. As new lesions were detected in several patients who missed their follow-up visit by only a few months, it seems appropriate to adhere to an annual surveillance protocol, until more data are available from large prospective cohorts.
Although not all patients with main-duct IPMN progress to cancer, the overall 10-year risk is estimated at approximately 25% \(^{21}\). Only 2 patients in the present study were identified with these lesions prior to surgery. After pathological evaluation of the resection specimen 4 cystic lesions were reclassified as main-duct IPMN. Discrepancy between imaging and pathology is not an uncommon finding in this situation \(^{22}\).

The present study also sought to identify looked for risk factors that can easily be assessed preoperatively for association with high-risk neoplastic precursor lesions or PDAC in the resection specimens. Multivariable analyses showed age $\geq 65$, female gender, carriage of a gene mutation and location of a lesion in the head/uncinate region of the pancreas to be associated with the detection of a high-risk precursor lesion or PDAC in the resection specimen. Among female carriers of a gene mutation aged above 65 with a lesion suspicious for malignancy in the head/uncinate region of the pancreas, one should carefully weigh the option of pancreatic surgery versus continuing surveillance.

Survival analysis indicated that this was strongly influenced by the stage of disease at diagnosis \(^{23}\). Importantly, the survival of patients with high-risk neoplastic precursors in their resection specimen was equal to those with no or low-risk neoplastic lesions, emphasizing the need to reliably identify high-risk precursor lesions more than early cancers.

The strength of this study is the international pooling of data on PDAC-surveillance programmes. This yielded a unique and sizeable cohort of high-risk patients participating in PDAC-surveillance programmes in whom either a suspicious lesion was detected for which they underwent surgery, or in whom an inoperable pancreatic cancer developed. The main limitations of this study are its design and
potential lead-time and length bias\textsuperscript{24}. Another limitation is that differences between protocols of the centres existed, particularly before publication of consensus statements of the Cancer of the Pancreas Screening (CAPS) Consortium in 2013\textsuperscript{17}. Although this is the largest cohort described, its sample size is still too limited to assess differences in survival between R0 and R1 resections. Another limitation is the lack of detailed information of all 1700 high-risk individuals who underwent surveillance. Attention was specifically focused on the highly selected group who either developed advanced neoplasia or underwent pancreatic surgery and this study has added new, interesting and valuable data to the literature that provides some rationale to screening individuals at high risk for pancreatic cancer. More research is needed to better understand the risk factors for individuals at high risk of developing PDAC, and improve the selection of high-risk individuals for surgery. Collaborating internationally in large worldwide prospective studies seems the logical way forward.
Table 1. Baseline characteristics of all high-risk individuals who underwent surgery due to the detection of a suspicious pancreatic lesion or who were diagnosed with advanced pancreatic cancer during participation in PDAC surveillance.

|                                | High-risk individuals who underwent surgery (n=71) | High-risk individuals who were diagnosed with advanced PDAC (n=5) |
|--------------------------------|--------------------------------------------------|------------------------------------------------------------------|
| **Age at surgery or diagnosis of advanced PDAC, mean** (median, range, SD) | 60.3 (59.8, 36-80, 11.6) | 70.5 (65-80, 6.6) |
| **Gender, male**               | 37 (52.1%)                                       | 1 (20.0%)                                                       |
| **Race**                       |                                                  |                                                                  |
| White                          | 67 (94.4%)                                       | 5 (100.0%)                                                      |
| Black                          | 3 (4.2%)                                         | -                                                               |
| Other                          | 1 (1.4%)                                         | -                                                               |
| **Genetic background**         |                                                  |                                                                  |
| Familial pancreatic cancer (FPC) | 52 (73.2%)                                       | 4 (80.0%)                                                       |
| CDKN2A (FAMMM syndrome)        | 7 (9.9%)                                         | -                                                               |
| BRCA2 (HBOC)                   | 3 (4.2%)                                         | -                                                               |
| Peutz-Jeghers syndrome         | 3 (4.2%)                                         | 1 (20.0%)                                                       |
| BRCA1 (HBOC)                   | 1 (1.4%)                                         | -                                                               |
| TP53 (Li Fraumeni syndrome)    | 1 (1.4%)                                         | -                                                               |
| MMR (Lynch syndrome)           | 1 (1.4%)                                         | -                                                               |
| APC                            | 1 (1.4%)                                         | -                                                               |
| ATM                            | 1 (1.4%)                                         | -                                                               |
| PRRS1 (hereditary pancreatitis)| 1 (1.4%)                                         | -                                                               |
| **Number of FDR with PDAC, mean (median, range, SD)** | 1.5 (1.0, 0-3, 0.8) | 1.4 (0-2, 0.9) |
| **Number of SDR with PDAC, mean (median, range, SD)** | 1.1 (1.0, 0-4, 1.0) | 0.3 (0-1, 0.6) |
| **Youngest family member affected by PDAC, mean (range, SD)** | 55.5 (33-77, 10.8) | 63.3 (52-68, 7.5) |
| **Body mass index, mean (median, range, SD)** | 27.3 (26.6, 18-48, 5.1) | 26.1 (23-31, 3.7) |
| **Personal history of diabetes** | 11 (15.5%)                                       | 2 (40.0%)                                                       |
| **Number of months of diabetes prior to surgery or diagnosis of advanced PDAC, mean (median, range, SD)** | 36.6 (45.0, 0-63, 23.7) | 66 (12-120, 76.4) |
| **Personal history of pancreatitis** | 9 (12.7%)                                        | 1 (20.0%)                                                       |
| **Smoking behavior**           |                                                  |                                                                  |
| Never smoker                   | 46 (64.8%)                                       | 3 (60.0%)                                                       |
| Former smoker                  | 20 (28.2%)                                       | 2 (40.0%)                                                       |
| Current smoker                 | 3 (4.2%)                                         | -                                                               |
| No data                        | 2 (2.8%)                                         | -                                                               |
| ≥ 10 pack years in total       | 11 (15.5%)                                       | 1 (20.0%)                                                       |
| ≥ 20 pack years in total       | 4 (5.6%)                                         | -                                                               |
| **Alcohol consumption**        |                                                  |                                                                  |
| Never consumer                 | 38 (53.5%)                                       | 2 (40.0%)                                                       |
| Former consumer                | 12 (16.9%)                                       | 1 (20.0%)                                                       |
| Current consumer               | 19 (26.8%)                                       | 2 (40.0%)                                                       |
| Lesion characteristics | High-risk individuals who underwent surgery (n=71) | High-risk individuals who were diagnosed with advanced PDAC (n=5) |
|------------------------|----------------------------------------------------|-------------------------------------------------------------|
| Time point of lesion detection: | | |
| Baseline | 39 (54.9%) | 2 (40.0%) |
| Follow-up | 32 (45.1%) | 3 (60.0%) |
| Present at previous investigations | 9 (12.7%) | 1 (20.0%) |
| Mean months of lesion visualization prior to resection/diagnosis (median, range, SD) | 8.7 (5.0, 1-32, 9.5) | 41 (41, 41, -) |
| Case overdue for recommended screening | 10 (14.1%) | 1 (20.0%) |
| Mean months overdue for recommended screening (median, range, SD) | 6.7 (6.0, 1-12, 3.4) | 3 (3, 3,-) |
| Modality that detected the lesion (≥1 option possible): | | |
| EUS | 62 (87.3%) | 2 (40.0%) |
| MRI/MRCP | 29 (40.8%) | 3 (60.0%) |
| CT / PET-CT | 28 (39.4%) | 2 (40.0%) |
| ERCP | 8 (11.3%) | - |
| Lesion type of lesions that were reason for surgery (n=93) | | |
| Cystic | 44 (47.3%) | |
| Solid | 33 (35.5%) | |
| Hypoechoic | 3 (3.3%) | |
| Dilated pancreatic duct | 2 (2.2%) | |
| Features of chronic pancreatitis | 1 (1.1%) | |
| Other | 10 (10.8%) | |
| Lesion location (n=93) | | |
| Head/uncinate region | 35 (37.6%) | |
| Body | 20 (21.5%) | |
| Tail | 29 (31.2%) | |
| No data | 9 (9.7%) | |
| Lesion size in mm, mean (median, range, SD) | | |

PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; FAMMM, familial atypical multiple mole melanoma syndrome; HBOC, hereditary breast and ovarian cancer; MMR, mismatch repair genes; APC, adenomatous polyposis coli; ATM, ataxia telangiectasia mutated; FDR, first degree relative; SDR, second degree relative.

Table 2. Overview of lesion characteristics, type of surgery and pathology in all high-risk individuals who underwent surgery (n=71) and all high-risk individuals who were diagnosed with advanced disease (n=5) while participating in pancreatic cancer surveillance.
| Lesion Type                        | Number (95% CI)     |
|-----------------------------------|---------------------|
| All lesions (n=93)                | 14.0 (11.9, 3-51, 8.8) |
| Cystic lesions (n=44)             | 13.6 (11.6, 3-40, 8.0) |
| Solid lesions (n=33)              | 15.5 (13.0, 4-51, 10.0) |

| Neoadjuvant therapy              | N/A (N/A)           |
|----------------------------------|---------------------|
| **Type of surgery**              |                    |
| Distal pancreatectomy            | 36 (50.7%)          |
| Pancreatectoduodenectomy         | 18 (25.4%)          |
| Total pancreatectomy             | 9 (12.7%)           |
| Pancreatectoduodenectomy followed by completion pancreatectomy | 4 (5.6%) |
| Central pancreatectomy           | 2 (2.8%)            |
| Diagnosis of non-resectable disease during surgery | 2 (2.8%) |

| Complications of surgery (≥1 option possible) | |
|-----------------------------------------------|-----------|
| None                                          | 37 (52.1%) |
| Infectious complications                      | 10 (14.1%) |
| Delayed gastric emptying                      | 6 (8.5%)   |
| Pancreatic fistula                            | 4 (5.6%)   |
| Bile leak                                     | 2 (2.8%)   |
| Peri-pancreatic fluid collection              | 1 (1.4%)   |
| Other                                         | 6 (8.5%)   |
| No data                                       | 7 (9.9%)   |

| Pathology (≥1 could be present)              | |
|-----------------------------------------------|-----------|
| PDAC                                          | 19 (26.8%) |
| Main-duct IPMN with high-grade dysplasia      | 1 (1.4%)   |
| Main-duct IPMN with moderate-grade dysplasia  | 4 (5.6%)   |
| Main-duct IPMN with low-grade dysplasia       | 1 (1.4%)   |
| Mixed-duct IPMN with high-grade dysplasia     | 1 (1.4%)   |
| Mixed-duct IPMN with moderate-grade dysplasia | -          |
| Mixed-duct IPMN with low-grade dysplasia      | -          |
| Branch-duct IPMN with high-grade dysplasia    | 5 (7.0%)   |
| Branch-duct IPMN with moderate-grade dysplasia| 9 (12.7%)  |
| Branch-duct IPMN with low-grade dysplasia     | 16 (22.5%) |
| PanIN-3, multifocal                           | 3 (4.2%)   |
| PanIN-3, unifocal                             | 3 (4.2%)   |
| PanIN-2, multifocal                           | 35 (49.3%) |
| PanIN-2, unifocal                             | 10 (14.1%) |
| PanIN-1, multifocal                           | 32 (45.1%) |
| PanIN-1, unifocal                             | 4 (5.6%)   |
| Pancreatic neuroendocrine tumor ≥ 2 cm        | -          |
| Pancreatic neuroendocrine tumor < 2 cm        | 8 (11.3%)  |
| Incipient IPMN                                | 5 (7.0%)   |
| Serous cystadenoma                            | 2 (2.8%)   |
| Vascular malformation                         | 1 (1.4%)   |

| Highest grade of neoplastic lesion per HRI | |
|-------------------------------------------|-----------|
| PDAC                                      | 19 (26.8%) |
| Stage I/II PDAC                           | 16 (22.5%) |
| Stage III/IV PDAC                         | 3 (4.2%)   |
| Stage III/IV PDAC                         | 5 (100%)   |
| Tumor Type                                                  | Frequency | Notes |
|------------------------------------------------------------|-----------|-------|
| Main-duct IPMN with high-grade dysplasia                   | 1 (1.4%)  |       |
| Main-duct IPMN with moderate-grade dysplasia               | 2 (2.8%)  |       |
| Main-duct IPMN with low-grade dysplasia                    | 1 (1.4%)  |       |
| Branch-duct IPMN with high-grade dysplasia                 | 4 (5.6%)  |       |
| Branch-duct IPMN with moderate-grade dysplasia             | 7 (9.9%)  |       |
| Branch-duct IPMN with low-grade dysplasia                  | 9 (12.7%) |       |
| PanIN-3, multifocal                                        | 3 (4.2%)  |       |
| PanIN-3, unifocal                                          | 2 (2.8%)  |       |
| PanIN-2, multifocal                                        | 9 (12.7%) |       |
| PanIN-2, unifocal                                          | 7 (9.9%)  |       |
| PanIN-1, multifocal                                        | 1 (1.4%)  |       |
| PanIN-1, unifocal                                          | 1 (1.4%)  |       |
| Pancreatic neuroendocrine tumor < 2 cm                     | 3 (4.2%)  |       |
| Serous cystadenoma                                         | 2 (2.8%)  |       |

PDAC, pancreatic ductal adenocarcinoma; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; IPMN, intraductal papillary mucinous neoplasm; PanIN, pancreatic intraepithelial neoplasia; N/A, not applicable.
Table 3. Outcomes in all high-risk individuals who underwent surgery (n=71) and all high-risk individuals who were diagnosed with advanced disease (n=5) while participating in pancreatic cancer surveillance

| Follow-up time in mean months (median, range, SD) | High-risk individuals who underwent surgery (n=71) N (%) | High-risk individuals who were diagnosed with advanced PDAC (n=5) N (%) | P-value |
|--------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|---------|
| Survival                                         |                                                        |                                                               |         |
| Alive                                            | 59 (83.1%)                                             | 2 (40.0%)                                                     | 0.050   |
| Mean months after surgery/diagnosis (median, range, SD) | 54.3 (44.0, 0-168, 45.9)                             | 9.5 (3.5, 3-28, 12.3)                                         | < 0.001 |
| Long-term survival (≥ 3 years)                   | 37 (52.1%)                                             | 0                                                             |         |
| Mortality                                        |                                                        |                                                               |         |
| Died                                             | 12 (16.9%)                                             | 3 (60.0%)                                                     | 0.050   |
| Mean months after surgery/diagnosis (median, range, SD) | 54.3 (28.5, 5-164, 56.0)                             | 11.3 (3.0, 3-28, 14.4)                                        | 0.221   |
| Short-term mortality (≤ 1 year)                  | 2 (2.8%)                                               | 2 (40.0%)                                                     | 0.154   |
| PDAC-related                                     | 8 (11.3%)                                              | 3 (60.0%)                                                     | 0.506   |
| Non-PDAC-related                                 | 2 (2.8%)                                               | 0                                                             |         |
| Unknown cause of death                           | 2 (2.8%)                                               | 0                                                             |         |

PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation
Bold P-values were considered statistically significant
Table 4. Univariate and multivariate analyses for factors possibly associated with high-risk neoplastic precursor lesions or pancreatic ductal adenocarcinoma in the resection specimen

| Factors                                      | Univariate analyses | Multivariate analyses |
|----------------------------------------------|---------------------|-----------------------|
|                                              | Unadjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
| Age ≥65 at time of surgery                   | 4.108 (1.4-11.7)    | 0.007                | 7.530 (1.6-35.0)    | 0.010   |
| Female gender                                | 3.818 (1.4-10.3)    | 0.007                | 5.776 (1.4-24.3)    | 0.017   |
| White race                                   | 0.254 (0.0-2.6)     | 0.321                |                      |         |
| Carrier of a gene mutation                   | 2.395 (0.8-7.2)     | 0.113                | 4.918 (1.1-22.6)    | 0.040   |
| ≥2 first-degree relatives affected by PDAC   | 2.400 (0.9-6.4)     | 0.076                | 1.712 (0.4-7.2)     | 0.462   |
| Family member <50 affected by PDAC          | 1.150 (0.3-3.8)     | 0.820                |                      |         |
| Body Mass Index ≥25                          | 0.570 (0.2-1.7)     | 0.303                |                      |         |
| Personal history of diabetes                 | 1.829 (0.5-6.8)     | 0.505                |                      |         |
| Personal history of pancreatitis             | 0.686 (0.2-3.0)     | 0.727                |                      |         |
| Current or former smoker                     | 1.000 (0.4-2.7)     | 1.000                |                      |         |
| >10 pack years of smoking                    | 0.952 (0.1-6.3)     | 1.000                |                      |         |
| Current or former alcohol consumer           | 0.702 (0.3-1.8)     | 0.470                |                      |         |
| Detection of lesion at follow-up visit       | 1.142 (0.4-2.9)     | 0.782                |                      |         |
| Solid lesion type (vs cystic lesion)         | 1.111 (0.4-3.1)     | 0.839                |                      |         |
| Location of lesion in the head/uncinate region (vs location in body/tail) | 2.333 (0.8-6.6) | 0.105 | 4.232 (1.1-16.9) | 0.041 |
| Lesion size ≥1 centimeter                    | 1.260 (0.4-4.1)     | 0.702                |                      |         |
| Surgery after 2011                           | 1.473 (0.5-4.0)     | 0.448                |                      |         |

OR, odds ratio; CI, confidence interval; PDAC, pancreatic ductal adenocarcinoma.

Bold P-values were considered statistically significant.
Figure 1. Kaplan-Meier survival curve per subgroup

(Figure attached separately)

Legend:

A. Low-risk neoplastic lesions including pancreatic neuroendocrine tumors (PanNETs) <2 cm (n=39)
B. High-risk neoplastic lesions including all main-duct intraductal papillary mucinous neoplasms (IPMNs), branch-duct IPMNs with high-grade dysplasia and PanIN-3 lesions (n=13)
C. Stage I and II PDACs (n=16)
D. Stage III and IV PDACs (n=8)
ACKNOWLEDGEMENTS

On behalf of the participating centers of the CAncer of the Pancreas Screening (CAPS) Consortium (in alphabetical order):

Amsterdam Medical Center (The Netherlands), Beaujon Hospital (France), Columbia University Medical Center (USA), Creighton University Hereditary Cancer Center (USA), Dana Farber Cancer Institute (USA), Erasmus MC University Medical Center Rotterdam (The Netherlands), Icahn School of Medicine at Mount Sinai (USA), Indiana University (USA), Institut Paoli-Calmettes (France), Jefferson Medical Center (USA), Johns Hopkins Medical Institutions (USA), Mayo Clinic (USA), MD Anderson Cancer Center (USA), Medical College of Wisconsin (USA), Karolinska Institute (Sweden), Kyoto University Hospital (Japan), Ohio State University (USA), Pancreatic Cancer Action Network (USA), Rambam Healthcare Campus (Israel), St. Vincent’s Hospital (Australia), Teikyo University Medical Center (Japan), University Hospital of Verona (Italy), University Hospital of Santiago de Compostela (Spain), University Hospitals Case Medical Center (USA), University of Alabama (USA), University of Arizona (USA), University of California San Diego (USA), University of Colorado Denver (USA), University of Michigan (USA), University of Nebraska (USA), University of Pennsylvania (USA), University of Pittsburgh (USA), University of Southern California (USA), Yale University (USA), Vita-Salute San Raffaele University (Italy), Washington University (USA)

Foot note

No preregistration exists for the reported studies reported in this article
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016 doi: 10.3322/caac.21332 [published Online First: 2016/01/09]

2. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74(11):2913-21. doi: 0008-5472.CAN-14-0155 [pii]10.1158/0008-5472.CAN-14-0155 [published Online First: 2014/05/21]

3. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23(2):251-75. [published Online First: 1996/04/01]

4. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 2011;10(2):323-30. doi: 10.1007/s10689-010-9414-x [published Online First: 2011/01/06]

5. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142(4):796-804; quiz e14-5. doi: 10.1053/j.gastro.2012.01.005 [published Online First: 2012/01/17]

6. Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002;56(4 Suppl):S82-6. [published Online First: 2002/09/26]

7. Canto MI, Goggins M, Hruban RH, et al. Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clin Gastroenterol Hepatol 2006;4(6):766-81.

8. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009;104(9):2175-81. doi: 10.1038/ajg.2009.276 [published Online First: 2009/06/06]

9. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: A comprehensive strategy of imaging and genetics. Clin Cancer Res 2010;16(20):5028-37.

10. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011;106(5):946-54. doi: ajg201165 [pii]10.1038/ajg.2011.65 [published Online First: 2011/04/07]

11. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011;140(3):850-6. doi: S0016-5085(10)01738-5 [pii]10.1053/j.gastro.2010.11.048 [published Online First: 2010/12/07]

12. Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience. J Gastrointest Surg 2011 doi: 10.1007/s11605-011-1781-6 [published Online First: 2011/12/01]

13. Poletti TP, Schott I, Langer P, et al. Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 2013;19(2):442-9. doi: 1078-0432.CCR-12-2730 [pii]10.1158/1078-0432.CCR-12-2730 [published Online First: 2012/11/23]
14. Harinck F, Konings IC, Kluijt I, et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. *Gut* 2016;65(9):1505-13. doi: gutjnl-2014-308008 [pii]

15. Vasen H, Ibrahim I, Ponce CG, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. *J Clin Oncol* 2016;34(17):2010-9. doi: 10.1200/jco.2015.64.0730 [published Online First: 2016/04/27]

16. Roberts NJ, Norris AL, Petersen GM, et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. *Cancer discovery* 2016;6(2):166-75. doi: 10.1158/2159-8290.cd-15-0402 [published Online First: 2015/12/15]

17. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut* 2013;62(3):339-47. doi: 10.1136/gutjnl-2012-303108 [published Online First: 2012/11/09]

18. Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. *Am J Surg Pathol* 2006;30(9):1067-76. doi: pas.0000213265.84725.0b00000478-200609000-00001 [pii] [published Online First: 2006/08/26]

19. Toste PA, Kadera BE, Tatishchev SF, et al. Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. *J Gastrointest Surg* 2013;17(12):2105-13. doi: 10.1007/s11605-013-2360-9 [published Online First: 2013/10/09]

20. Fitzgerald TL, Mosquera C, Vora HS, et al. Indications for Surgical Resection in Low-Grade Pancreatic Neuroendocrine Tumors. *Am Surg* 2016;82(8):737-42. [published Online First: 2016/09/24]

21. Choi SH, Park SH, Kim KW, et al. Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2017;15(10):1509-20 e4. doi: 10.1016/j.cgh.2017.03.020

22. de Pretis N, Mukewar S, Aryal-Khanal A, et al. Pancreatic cysts: Diagnostic accuracy and risk of inappropriate resections. *Pancreatology* 2017;17(2):267-72. doi: 10.1016/j.pan.2017.01.002

23. Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. *J Surg Oncol* 2013;107(1):97-103. doi: 10.1002/jso.23267 [published Online First: 2012/09/20]

24. Morrison AS. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. *International journal of epidemiology* 1982;11(3):261-7. [published Online First: 1982/09/01]
